The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single agent olaparib in advanced oesophago-gastric cancer: Primary results from the SOlar clinical phase II single arm trial.
 
Georgina Keogh
No Relationships to Disclose
 
Elizabeth Cartwright
No Relationships to Disclose
 
Amina Tran
No Relationships to Disclose
 
Claire Saffery
No Relationships to Disclose
 
Oleg Zhitkov
No Relationships to Disclose
 
Becky Leamon
No Relationships to Disclose
 
Isma Rana
No Relationships to Disclose
 
Ed Johnston
No Relationships to Disclose
 
Madeleine Hewish
Honoraria - Pfizer
Consulting or Advisory Role - MSD Oncology
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Ailsa Sita-Lumsden
No Relationships to Disclose
 
Charlotte Fribbens
No Relationships to Disclose
 
Sheela Rao
Honoraria - Bayer; Incyte; Merck Serono; SERVIER (I)
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; GlaxoSmithKline; Hookipa Biotech; Merck Serono; SERVIER
Speakers' Bureau - Bayer; Merck Serono; SERVIER
Expert Testimony - Boehringer Ingelheim
Travel, Accommodations, Expenses - SERVIER
 
Ian Chau
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Jazz Pharmaceuticals; Novartis; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; BioNTech SE; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; Elevation Oncology; GlaxoSmithKline; Jazz Pharmaceuticals; Novartis; OncXerna Therapeutics; Seagen; SERVIER; Taiho Oncology; Takeda
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - BMS; Jazz Pharmaceuticals; SERVIER; Takeda
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); Bayer (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); Roche (Inst)
 
Naureen Starling
Honoraria - Astellas Pharma; AstraZeneca; BMS; BMS; Daiichi Sankyo; GlaxoSmithKline; Merck; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Natera; Pierre Fabre; Pierre Fabre; Pierre Fabre; Seagen; SERVIER; SERVIER; SERVIER; Tempus
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb; Gilead Sciences; GlaxoSmithKline; Janssen; Moderna Therapeutics; MSD Oncology; Seagen; Takeda
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; GlaxoSmithKline; Guardant Health; MSD Oncology; SERVIER; Takeda
(OPTIONAL) Uncompensated Relationships - Guardant Health